BioMérieux BIOFIRE Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 Becomes First COVID-19 Diagnostic Test to Obtain De Novo FDA Authorization
|
By HospiMedica International staff writers Posted on 19 Mar 2021 |
|
Image: BIOFIRE RP2.1 Panel (Photo courtesy of BioMérieux)
BioMérieux (Marcy-l'Étoile, France) has received US Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE RP2.1 Panel, making it the first SARS-CoV-2 diagnostic test of any kind to be granted De Novo status by US FDA.
The panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease). The panel was granted De Novo status by US FDA after having gone through the normal US FDA review pathway outside of the Emergency Use Authorization (EUA) track. The De Novo authorization will be concurrent with the revocation of the US FDA EUA that was obtained on May 1, 2020 for the panel. The BIOFIRE RP2.1 Panel EUA and De Novo kits are identical with the exception of changes to the labeling.
The BIOFIRE RP2.1 Panel allows healthcare providers to quickly identify common respiratory pathogens found in patients presenting with acute respiratory tract infection, using one simple test. The BIOFIRE RP2.1 Panel yields results in approximately 45 minutes using nasopharyngeal swab (NPS) samples in transport media or saline. It runs on the fully automated BIOFIRE FILMARRAY 2.0 and BIOFIRE Torch Systems with only two minutes of sample preparation time.
The De Novo application was supported by a multicenter prospective clinical study in which the performance of the BIOFIRE RP2.1 Panel SARS-CoV-2 assay was evaluated in over 500 specimens against a combined reference of three independent molecular SARS-CoV-2 assays, each with U.S. FDA EUA designation. The BIOFIRE RP2.1 Panel SARS-CoV-2 assay demonstrated positive percent agreement (PPA) of 98.4% and negative percent agreement (NPA) of 98.9%.
“The De Novo authorization of the BIOFIRE RP2.1 Panel demonstrates how BioFire is dedicated to responding to a rapidly-evolving global pandemic with urgency and accuracy. This is the first US FDA De Novo authorized COVID-19 test,” said Pierre Boulud, Chief Operating Officer, Clinical Operations of bioMérieux.
Related Links:
BioMérieux
The panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease). The panel was granted De Novo status by US FDA after having gone through the normal US FDA review pathway outside of the Emergency Use Authorization (EUA) track. The De Novo authorization will be concurrent with the revocation of the US FDA EUA that was obtained on May 1, 2020 for the panel. The BIOFIRE RP2.1 Panel EUA and De Novo kits are identical with the exception of changes to the labeling.
The BIOFIRE RP2.1 Panel allows healthcare providers to quickly identify common respiratory pathogens found in patients presenting with acute respiratory tract infection, using one simple test. The BIOFIRE RP2.1 Panel yields results in approximately 45 minutes using nasopharyngeal swab (NPS) samples in transport media or saline. It runs on the fully automated BIOFIRE FILMARRAY 2.0 and BIOFIRE Torch Systems with only two minutes of sample preparation time.
The De Novo application was supported by a multicenter prospective clinical study in which the performance of the BIOFIRE RP2.1 Panel SARS-CoV-2 assay was evaluated in over 500 specimens against a combined reference of three independent molecular SARS-CoV-2 assays, each with U.S. FDA EUA designation. The BIOFIRE RP2.1 Panel SARS-CoV-2 assay demonstrated positive percent agreement (PPA) of 98.4% and negative percent agreement (NPA) of 98.9%.
“The De Novo authorization of the BIOFIRE RP2.1 Panel demonstrates how BioFire is dedicated to responding to a rapidly-evolving global pandemic with urgency and accuracy. This is the first US FDA De Novo authorized COVID-19 test,” said Pierre Boulud, Chief Operating Officer, Clinical Operations of bioMérieux.
Related Links:
BioMérieux
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Resorbable Bovine Collagen Membrane
GenDerm
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
AI Tool Predicts Chronic Kidney Disease Risk in Diabetes
Chronic kidney disease is a common and serious complication of type 2 diabetes and often progresses without obvious early symptoms, increasing morbidity and straining health systems. Many risk models were... Read more
AI Trends Report Guides Responsible, Effective Healthcare Deployment
Hospitals are under growing pressure to adopt artificial intelligence tools that improve safety, efficiency, and continuity of care without compromising quality. At the same time, clinicians need clearer... Read more
Critical Care
view channel
Wearable Microneedle Patch Monitors Antibiotic Levels in Real Time
Therapeutic drug monitoring for agents with narrow therapeutic windows often relies on intermittent blood draws and laboratory analysis, providing only snapshots of exposure. Real-time, minimally invasive... Read more
AI Analysis of EMS Calls Aids Pediatric Trauma Decision-Making
Accurate trauma triage is difficult when decisions rely on brief, noisy reports from emergency medical services (EMS). Misclassification can delay lifesaving interventions or lead to overuse of critical... Read more
Surgical Techniques
view channel
AI-Designed Microneedle Patch Accelerates Diabetic Wound Healing
Chronic diabetic wounds are slow to heal and prone to infection, often leading to repeated procedures and prolonged care. Standard closure methods bring wound edges together but do not adapt to changing... Read more
Focused Ultrasound System Gains CE Mark for Liver Tumor Treatment
Liver tumors remain a major global health challenge, and many patients are not candidates for resection or conventional thermal ablation. Tumor location, underlying liver disease, and other clinical factors... Read more
Patient Care
view channel
AI Avatar Doctor Improves Patient Understanding Before Radiotherapy
Radiation oncology consultations require patients to grasp complex concepts quickly, yet anxiety and information overload often undermine understanding and informed consent. Poor comprehension can also... Read more
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Health IT
view channel
Weekly Remote Symptom Monitoring Improves Symptom Control in Advanced Cancer
Patients receiving treatment for advanced cancer often struggle with uncontrolled symptoms and fragmented communication with clinicians. These gaps can impair daily function, increase emergency department... Read more
Digital Heart Model Supports Targeted Ablation in Atrial Fibrillation
Atrial fibrillation is an erratic, quivering heartbeat and a leading cause of stroke. Catheter ablation is widely used to interrupt arrhythmogenic tissue, yet many patients—especially with persistent ... Read more
Point of Care
view channel
New Brain Ultrasound Platform Enables Bedside Postoperative Imaging
Transporting postoperative patients for CT or MRI can create operational burdens, delays, and disruptions in care. Bedside visualization may help reduce transport demands, lower radiation exposure, and... Read more
Handheld Ultrasound Expands Point-of-Care Imaging Access in Brazil
Rapid access to diagnostic imaging is essential across hospitals, emergency departments, clinics, and municipal health systems, but large markets still face uneven availability, particularly in rural regions.... Read more
Business
view channel
AI Care Platform Adds Quantitative MRI Analysis for Multiple Sclerosis
Neurodegenerative diseases such as multiple sclerosis require timely identification and coordinated, long-term management. As health systems seek consistent decision-making at scale, quantitative neuroimaging... Read more
